Copyright 2008 Medical News Today Latest Lung Cancer News From Medical News Today. http://www.medicalnewstoday.com/sections/lung_cancer/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Wed, 14 May 2008 04:00:00 PDT http://www.medicalnewstoday.com/articles/107326.php Oregon Health & Science University Cancer Institute researchers have pinpointed the protein that can lead to genetic changes that cause lung cancer.The research is published in the British Journal of Cancer.Researchers discovered that the production of a protein called FANCD2 is slowed when lung cells are exposed to cigarette smoke. Low levels of FANCD2 leads to DNA damage, triggering cancer. Tue, 13 May 2008 04:00:00 PDT http://www.medicalnewstoday.com/articles/107271.php In a leading study that has implications for the development of novel therapies for a number of breast, lung and ovarian cancers that have lost the expression of a gene called glypican-3 (GPC3), Sunnybrook researchers have discovered how the loss of the GPC3 gene induces overgrowth through certain growth factors such as Sonic Hedgehog which stimulate cancer growth. Tue, 13 May 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/107121.php GlaxoSmithKline (GSK) announced that oral Hycamtin® (topotecan hard capsules) have received approval from the European Commission for the treatment of relapsed SCLC. Specifically, topotecan hard capsules are indicated as monotherapy for the treatment of adult patients with relapsed SCLC (PS0-2 [*]) [1] for whom re-treatment with the first-line regimen is not considered appropriate. Mon, 05 May 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/106147.php AstraZeneca announced the submission of a marketing authorisation application to the European Medicines Agency (EMEA) for its oral anti-cancer drug, gefitinib (IRESSATM) as a treatment for locally advanced or metastatic NSCLC in patients who have been pre-treated with platinum-containing chemotherapy. Sat, 03 May 2008 03:00:00 PDT http://www.medicalnewstoday.com/articles/105951.php Several herbs with diversified pharmacological properties are known to be rich sources of chemical constituents that may have potential for the treatment of several human cancers. Thu, 01 May 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/105878.php Compugen Ltd. (NASDAQ:CGEN) announced the discovery and experimental verification of CGEN-438, a potential blood based biomarker for lung cancer. CGEN-438 is novel splice variant peptide of delta-like protein 3 precursor (DLL3). Importantly, the Compugen discovered biomarker is a peptide that is secreted from the cell into the bloodstream, whereas the previously known DLL3 is a protein located on the cell membrane. Thu, 01 May 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/105888.php Vicus Therapeutics, LLC, a biopharmaceutical company focused on oncology supportive care, announced today the completion of the last patient visit in its study VT1-CAX-001, a Phase 2 trial of VT-122. The compound was tested for the treatment of cachexia in weight losing subjects with Stage IV, non-small cell lung cancer (NSCLC). The Phase 2 clinical trial was conducted in India and the final study report is expected in June 2008. Sun, 27 Apr 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/105498.php Monotherapy treatment with the triple angiokinase inhibitor1 BIBF 1120 (planned tradename Vargatef ™) offers promising efficacy and is well tolerated in patients with advanced, relapsed non small cell lung cancer (NSCLC), according to results from a phase II study in patients with lung cancer2. Sat, 26 Apr 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/105398.php Monotherapy treatment with the triple angiokinase inhibitor1 BIBF 1120 (planned tradename VARGATEF™) offers promising efficacy and is well tolerated in patients with advanced, relapsed non-small cell lung cancer (NSCLC), according to results from a phase II study in patients with lung cancer2. Fri, 25 Apr 2008 08:00:00 PDT http://www.medicalnewstoday.com/articles/105387.php A clinical trial evaluating the benefit of adding the drug sorafenib to the combination of carboplatin/paclitaxel chemotherapy for lung cancer patients has been stopped based on results from an interim analysis, after an independent data monitoring committee concluded that the study would not meet its primary endpoint of improved overall survival. Fri, 25 Apr 2008 08:00:00 PDT http://www.medicalnewstoday.com/articles/105334.php New results on genetic techniques that are helping doctors diagnose and treat lung cancer were released today at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) in Geneva, Switzerland. In one report (Abstract No. Fri, 25 Apr 2008 06:00:00 PDT http://www.medicalnewstoday.com/articles/105337.php A groundbreaking free tool to help oncologists choose the best therapies for patients with non-small-cell lung cancer has been launched this week by scientists at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) in Geneva, Switzerland. Fri, 25 Apr 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/105338.php Papers presented at the 1st European Lung Cancer Conference, jointly organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) in Geneva, Switzerland highlight emerging evidence that common viruses may contribute to the development of lung cancer. Experts agree that smoking is by far the most important factor that contributes to lung cancer development. But other factors can play a role in some cases. Fri, 25 Apr 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/105339.php New, long-term results from a clinical trial presented today at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association of the Study of Lung Cancer (IASLC) show that MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic), an immune-boosting treatment for lung cancer patients, reduces the risk of relapse after surgery -- to the same extent as chemotherapy but without the side-effects of chemotherapy. Thu, 24 Apr 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/105127.php Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced that final efficacy results from its Phase 2 clinical trial of picoplatin confirming previously announced interim results showing a survival benefit in patients with recurrent small cell lung cancer (SCLC) who have failed prior platinum-containing first-line chemotherapy or who have progressed within six months of first-line therapy. Mon, 21 Apr 2008 15:00:00 PDT http://www.medicalnewstoday.com/articles/104796.php Genentech, Inc. (NYSE:DNA) announced an update for the previously reported Roche-sponsored international Phase III clinical study (AVAiL) of Avastin® (bevacizumab) in combination with gemcitabine and cisplatin chemotherapy, in patients with advanced, non-squamous, non-small cell lung cancer (NSCLC). Mon, 21 Apr 2008 04:00:00 PDT http://www.medicalnewstoday.com/articles/104781.php Nereus Pharmaceuticals, Inc., a pioneer in drug discovery from marine microbial sources, announced that enrollment has begun in a Phase 1b study evaluating the proteasome inhibitor NPI-0052 in combination with vorinostat (Zolinza®, Merck & Co.) in patients with selected solid tumor malignancies. The open-label study will enroll approximately 40 patients with advanced non-small cell lung cancer, pancreatic cancer or melanoma for whom standard approved therapy is not available. Mon, 21 Apr 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/104743.php Eli Lilly and Company (NYSE: LLY) announced that European health authorities have approved the use of ALIMTA® (pemetrexed for injection) for a histologically-based use in the first-line treatment of advanced non-small-cell lung cancer (NSCLC), the most common form of lung cancer. Thu, 17 Apr 2008 04:00:00 PDT http://www.medicalnewstoday.com/articles/104390.php Although fewer of them undergo surgery, lung cancer patients in their 80s fare equally well following surgery as their younger counterparts, researchers report. The findings offer doctors potentially valuable guidance in treatment options for elderly patients, according to researchers. A research team from the Hoag Cancer Center in Newport Beach, California, observed 1,293 patients with lung cancer, 482 of whom underwent surgical treatment. Thu, 17 Apr 2008 03:00:00 PDT http://www.medicalnewstoday.com/articles/104373.php Doctors may be able to determine the extent of a smoker's lung damage by looking in his or her mouth, according to new research from The University of Texas M. D. Anderson Cancer Center. Thu, 17 Apr 2008 03:00:00 PDT http://www.medicalnewstoday.com/articles/104351.php Irregular molecules in the lining of the mouth, the saliva, the fallopian tube or the bladder can identify early stage cancer, according to research presented at the 2008 Annual Meeting of the American Association for Cancer Research, April 12 - 16. Scientists who hope to apply basic knowledge to medical practice are developing tests that diagnose, predict or monitor cancer risks without invasive tissue sampling. Tue, 15 Apr 2008 04:00:00 PDT http://www.medicalnewstoday.com/articles/104046.php U.S. researchers have reported that damage to cells lining the mouth can predict similar damage in the lungs which eventually leads to lung cancer in smokers.They hope in the future that it may be possible to swab the mouths of smokers to predict who is developing lung cancer, saving painful and dangerous biopsies of the lung. Tue, 15 Apr 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/103957.php Kosan Biosciences Incorporated (Nasdaq: KOSN) announced that the Phase 2 trial of epothilone KOS-1584 in patients with non-small cell lung cancer has been initiated. The Phase 2 trial is an open-label, multi-center, monotherapy study of KOS-1584 in patients with measurable advanced or metastatic non-small cell lung cancer who have previously received only one prior chemotherapy regimen. The primary endpoint of the Phase 2 trial is objective response rate. Tue, 15 Apr 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/103951.php Alfacell Corporation (Nasdaq: ACEL) announced that Dr. Intae Lee with the University of Pennsylvania has reported that Alfacell's ONCONASE (ranpirnase) could be a promising radiation sensitizer for lung cancer treatment. Dr. Lee presented the pre-clinical in vivo and in vitro data in a poster at the 2008 American Association of Cancer Research (AACR) Annual Meeting being held April 12 - 16 in San Diego. Mon, 14 Apr 2008 16:00:00 PDT http://www.medicalnewstoday.com/articles/103914.php According to an article published in the Journal ofEpidemiology and Community Health, excess pneumonia deaths inEngland are associated with engine exhaust fumes. Author E G Knoxcompares the total annual losses of pneumonia due to air pollution tothat of the London smog in 1952.